Risk of serious and fatal adverse events with sorafenib use in patients with solid cancers

Описание к видео Risk of serious and fatal adverse events with sorafenib use in patients with solid cancers

Dr Gyawali meets with ecancertv at ESMO 2016 to discuss the safety profile of sorafenib, with a 27% increase in the risk of grade 4 and 5 adverse events compared to standard care.

He describes the context of the results from this meta-analysis, considering the balancing of risk and outcome for patients, and the impact of treatment-related hospitalisation on quality of life.

Dr Gyawali spoke further with ecancer about his upcoming publication in ecancers' medical journal, coming soon, and contributes a regular blog with his views on recent research.

Комментарии

Информация по комментариям в разработке